Evidence map›Paper›PMID 30186614›Full record

ArticleCanadian journal of kidney health and disease2018

The Risk of Adverse Events in Patients With Polycystic Kidney Disease With Advanced Chronic Kidney Disease.

Sonali de Chickera, Ayub Akbari, Adeera Levin, Mila Tang, Pierre Brown, Ognjenka Djurdev, Mohan Biyani, Edward G Clark, Manish M Sood

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Canadian journal of kidney health and disease, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Cardiovascular Manifestations and Management in ADPKD.Kidney international reports · 2023
    Review
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Sonali de ChickeraDepartment of Medicine, University of Ottawa, Ontario, Canada.
Ayub AkbariDepartment of Medicine, University of Ottawa, Ontario, Canada.
Adeera LevinBC Renal Agency, Vancouver, Canada.
Mila TangUniversity of British Columbia, Vancouver, Canada.
Pierre BrownDepartment of Medicine, University of Ottawa, Ontario, Canada.
Ognjenka DjurdevUniversity of British Columbia, Vancouver, Canada.
Mohan BiyaniDepartment of Medicine, University of Ottawa, Ontario, Canada.
Edward G ClarkDepartment of Medicine, University of Ottawa, Ontario, Canada.
Manish M SoodDepartment of Medicine, University of Ottawa, Ontario, Canada.
University of Ottawa · CAUniversity of British Columbia · CABC Cancer Agency · CAInstitute for Clinical Evaluative Sciences · CAOttawa Hospital Research Institute

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPolycystic kidney disease (PKD) leads to progressive chronic kidney disease (CKD) with a subsequent risk of adverse events such as cardiac disease, infections, end-stage kidney disease (ESKD), and mortality.

objectivesTo determine the risks of CKD-related adverse outcomes in patients with PKD compared with patients without PKD.

settingCanadian study of prediction of death, dialysis and interim cardiovascular events (CanPREDDICT) was a prospective pan-Canadian cohort study from 2008-2013 involving 28 facilities with adjudicated outcomes. PATIENTS: Adult CKD patients (estimated glomerular filtration rate [eGFR] = 15-45 mL/min/1.73 m MEASUREMENTS: Polycystic kidney disease as identified by the treating physician.

methodsPatients with PKD (PKD) and non-PKD were propensity score (PS) matched (1:4) using demographics, comorbidities, and laboratory values. We used conditional Cox proportional hazards models to examine the risk of cardiac disease (defined as coronary artery disease or congestive heart failure), infection, ESKD, or all-cause mortality in patients with PKD compared with no PKD.

resultsAmong a total of 2370 patients, 105 with PKD were matched with 416 without PKD with a baseline mean age and eGFR of 62.6 years and 27.8 mL/min, respectively. During 1680 person-years of follow time (median follow-up: 3.8 years), there were a total of 43 cardiac, 83 ESKD, 117 infectious, and 39 all-cause mortality events. PKD was associated with a higher risk of cardiac events (9.5% vs 7.9%, hazard ratio [HR] = 1.46, 95% confidence interval [CI] = 1.04-2.04) and ESKD (25.7% vs 13.5%, HR = 2.00, 95% CI = 1.33-3.01), and with similar risks for infection (21.9% vs 22.6%, HR = 1.16, 95% CI = 0.75-1.82) or all-cause mortality (6.7% vs 7.7%, HR = 0.87, 95% CI = 0.40-1.91) compared with non-PKD. There were no differences in the types of infections (urinary, respiratory, hematologic, or other) between the 2 groups (

conclusionsPatients with PKD with advanced CKD are at a potentially higher risk of ESKD and cardiac events compared with patients without PKD. These findings, if confirmed in larger cohorts, suggest that monitoring and treatment for adverse outcomes in patients with PKD, especially related to cardiac disease, may be beneficial.

Indexed as

cardiac eventschronic kidney diseaseend-stage kidney diseaseinfectionmortalitypolycystic kidney disease

Identifiers

PMID30186614
PMCPMC6117870
OpenAlexW2806299369

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.